MODEL VERDICT
Aimei Health Technology Co., Ltd (AFJK)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| May 1, 2026 | NEUTRAL | 0.15 | $46.18 | CURRENT | — |
| Apr 24, 2026 | NEUTRAL | 0.15 | $47.20 | CURRENT | — |
| Apr 17, 2026 | NEUTRAL | 0.15 | $45.31 | CURRENT | — |
| Apr 16, 2026 | NEUTRAL | 0.15 | $51.20 | CURRENT | — |
| Apr 10, 2026 | NEUTRAL | 0.16 | $56.00 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| Industry Median P/E 4 industry peers | $7.22 | -84.4% | 30% | A | Peer Data |
| Price / Book 5 industry peers | $20.85 | -54.9% | 25% | B | Model Driven |
| Price / Tangible Book 4 bank peers | $25.39 | -45.0% | 20% | B+ | Bank Primary |
| Earnings Yield 4 industry peers | $6.18 | -86.6% | 8% | B | Data |
| Weighted Output Blended model output | $14.69 | -68.2% | 100% | 59 | SIGNIFICANTLY OVERVALUED |
| EPS Growth ↓ | P/E Multiple → | 139× | 152× | 165× (Current) | 178× | 191× |
|---|---|---|---|---|---|
| Bear Case (4%) | $40 | $44 | $48 | $52 | $56 |
| Conservative (7%) | $41 | $45 | $49 | $53 | $57 |
| Base Case (10.0%) | $43 | $47 | $51 | $55 | $59 |
| Bull Case (14%) | $44 | $48 | $52 | $57 | $61 |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
Based on our peer multiples analysis with 8 valuation metrics, the model estimates AFJK's fair value at $14.69 vs the current price of $46.18, implying -68.2% downside potential. Model verdict: Significantly Overvalued. Confidence: 59/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $14.69 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $11.90 (P10) to $19.39 (P90), with a median of $15.67.
AFJK's current P/E of 164.9x compares to the industry median of 25.8x (4 peers in the group). This represents a +539.3% premium to the industry. The historical average P/E is N/Ax over 0 years. Signal: High Premium.
No analyst coverage data is available for AFJK.
The model confidence score is 59/100, based on: data completeness (24), peer quality (22), historical depth (5), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for AFJK.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.